Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Developments Grow a Business Value with CAGR of 12.3% Till the Forecast 2025
Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Research by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) – Forecast till 2025
Pune, India – August 20, 2019 /MarketersMedia/ —
Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Overview
Idiopathic Pulmonary Fibrosis Treatment is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases. However, the high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment market.
The Global Idiopathic Pulmonary Fibrosis Treatment Market is expected to register a CAGR of 12.3% during the forecast period of 2019 to 2025, with a market value of USD 2,237 million in 2018.
Additionally, rising prevalence rates of lung diseases coupled with increasing geriatric population is anticipated to fuel the market growth. For instance, according to the Office for National Statistics in 2017, approximately 18% and 2.4% of the total UK population was aged over 65 years and 85 years, respectively. On the other hand, the high cost of surgery is projected to hamper the growth of the market during the assessment period.
We Offer you to Get a FREE Sample at https://www.marketresearchfuture.com/sample_request/6791
“Idiopathic Pulmonary Fibrosis (IPF) Treatment Market” Research report provide valuable insight with following companies, which includes –
Boehringer Ingelheim GMBH
Biogen
Novartis AG
Medicinova Inc.
Bristol-Myers Squibb Company
Galapagos NV
Hoffmann-La Roche AG
Fibrogen Inc.
Cipla
Merck & Co. Inc.
Prometic Life Sciences Inc. and others.
The “Idiopathic Pulmonary Fibrosis Treatment Market” highlights the information about the industries and market, technologies, and abilities over the trends and the developments of the industries. Readers are provided with a detailed outlook of the global Idiopathic Pulmonary Fibrosis Treatment Market, which includes carefully calculated revenue and volume growth, CAGR, and market share estimations.
LIST OF TABLES
Table 1 Global Idiopathic Pulmonary Fibrosis Treatment Market Synopsis, 2016–2025
Table 2 Global Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecast, 2016–2025 (USD Million)
Table 3 Global Idiopathic Pulmonary Fibrosis Treatment Market, By Treatment, 2016–2025 (USD Million)
Table 4 Global Idiopathic Pulmonary Fibrosis Treatment Market, By Region, 2016–2025 (USD Million)
Table 5 North America: Idiopathic Pulmonary Fibrosis Treatment Market, By Treatment, 2016–2025 (USD Million)
Table 6 US: Idiopathic Pulmonary Fibrosis Treatment Market, By Drug Class, 2016–2025 (USD Million)
Table 7 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, By Treatment, 2016–2025 (USD Million)
Table 8 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, By Drug Class, 2016–2025 (USD Million)
…To be Continued.
Segmentation
The global IPF treatment market has been segmented based on treatment.
The market, based on treatment, has been further divided into drug class, oxygen therapy, lung transplant, and others. The drug class segment is likely to hold a major share in the market due to the increasing adoption of the drugs for the treatment of IPF and wider preferability. The oxygen therapy segment is predicted to be the fastest growing due to the increasing inclination of medical professionals towards this therapy for the treatment of IPF.
IPF is a lung disease which causes the tissue in your lungs to become stiff. The global IPF treatment market is driven by factors such as increasing cases of IPF and growing demand for minimally invasive procedures to diagnose and treat different chronic diseases. For instance, FibroGen, Inc. announced that the grant of Fast Track designation by US Food and Drug Administration (FDA) for the company’s anti-CTGF antibody, Pamrevlumab, for the treatment of patients with IPF.
Access complete Premium Research Report along with TOC, List of Figures and Tables at https://www.marketresearchfuture.com/reports/stereotactic-surgery-devices-market-6791
Global Idiopathic Pulmonary Fibrosis Treatment Market, by Region:
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The IPF treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
The European IPF treatment market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The IPF treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The IPF treatment market in the Middle East & Africa has been divided into the Middle East and Africa.
About Market Research Future: Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
Contact Info:
Name: Mr Akash Anand
Email: Send Email
Organization: Market Research Future
Address: Magarpatta Road, Hadapsar, Pune
Phone: +1 646 845 9312
Website: https://www.marketresearchfuture.com/reports/idiopathic-pulmonary-fibrosis-treatment-market-8109
Source: MarketersMedia
Release ID: 88909907
Copyright © 1999-2013 SproutNews.com
